First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

Published: 5 August 2022| Version 1 | DOI: 10.17632/bdjx5bcgtw.1
Contributors:
Chang Gon Kim,
Miso Kim,
Jieon Hwang,
Seung Tae Kim,
Minkyu Jung,
Kyoo Hyun Kim,
Kyung Hwan Kim,
Jee Suk Chang,
Woong Sub Koom,
Mi Ryung Roh,
Kee Yang Chung,
Tae Min Kim,
Sang Kyum Kim,
Jeeyun Lee,
Sang Joon Shin

Description

This is a supplementary material for the article JAAD-D-22-01092R1, First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.

Files

Categories

Dermatology, Medical Oncology

License